Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structural basis of the oncogenic KRAS mutant and GJ101 complex.

Biochemical and biophysical research communications - 22 Jan 2023

Kim Hyeon Jin, Han Chang Woo, Jeong Mi Suk, Jang Se Bok

Abstract excerpt

KRAS mutations occur in a quarter of all human cancers. When activated in its GTP-bound form, RAS stimulates diverse cellular systems, such as cell division, differentiation, growth, and apoptosis through the activations of various signaling pathways, which include mitogen-activated protein kinase (MAPK), phosphoinositide 3 kinases (PI3K), and RAL-GEFs pathways. We found that GJ101 (65LYDVA69) binds directly to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line
Share to Cell Line, Tumor
Share to Guanosine Triphosphate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinases

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Signal Transduction

Source

Identifiers

PMID: 36516586
DOI: 10.1016/j.bbrc.2022.12.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structural basis of the oncogenic KRAS mutant and GJ101 complex.PMID 36516586Read ↗

A H-REV107 Peptide Inhibits Tumor Growth and Interacts Directly with Oncogenic KRAS MutantsSemantic proximity Read ↗

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.Semantic proximity Read ↗

Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.Semantic proximity Read ↗

KRAS: From undruggable to a druggable Cancer Target.Semantic proximity Read ↗

Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.Semantic proximity Read ↗

Identification of novel peptide inhibitors for oncogenic KRAS G12D as therapeutic options using mutagenesis-based remodeling and MD simulations.Semantic proximity Read ↗

Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRASSemantic proximity Read ↗

In silico comparative analysis of KRAS mutations at codons 12 and 13: Structural modifications of P-Loop, switch I&II regions preventing GTP hydrolysis.Semantic proximity Read ↗

KRAS p.G12C Mutation in Metastatic Colorectal Cancer: Prognostic Implications and Advancements in Targeted TherapiesSemantic proximity Read ↗

Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.Semantic proximity Read ↗

Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer CellsSemantic proximity Read ↗

The Endeavours in RAS Inhibition - the Past, Present, and Future.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.